GlobeNewswire: Neoleukin Therapeutics, Inc. Contains the last 10 of 179 releaseshttp://www.globenewswire.com/External?Length=42024-03-28T12:03:05ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2023/12/15/2796782/0/en/Neoleukin-Therapeutics-Announces-1-for-4-Reverse-Stock-Split.html?f=22&fvtc=4&fvtv=21142Neoleukin Therapeutics Announces 1-for-4 Reverse Stock Split2023-12-15T00:00:00Z<![CDATA[SEATTLE, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” or the “Company” (NASDAQ:NLTX), a biopharmaceutical company that has designed de novo protein therapeutics utilizing sophisticated computational methods, today announced that its Board of Directors (“Board”) has approved a reverse stock split of the Company’s outstanding shares of common stock at a ratio of 1-for-4. The reverse stock split will become effective at 12:02 a.m., Eastern Time on December 18, 2023. The Company's common stock is expected to begin trading on a post-reverse stock split basis on the Nasdaq Global Market on December 19, 2023, under the new name Neurogene Inc. and under the new symbol "NGNE" following the anticipated closing of the merger with Neurogene Inc. (the “Merger”), with a new CUSIP number 64135M105. The reverse stock split was effected to ensure the combined company’s compliance with the minimum bid price requirement of $4.00 per share for initial listing on the Nasdaq Global Market. The reverse stock split was approved by Neoleukin’s stockholders at the Company’s special meeting of stockholders held on December 13, 2023, to be effected in the Board’s discretion within approved parameters of not less than 1-for-1.5 and not more than 1-for-5. The final reverse stock split ratio was approved by the Board on December 13, 2023. The reverse stock split is expected to reduce the number of shares of the Company’s outstanding common stock from approximately 9,398,497 shares to approximately 2,349,624 shares. The number of shares of the Company's authorized common stock was not affected by the reverse stock split, but at the special meeting of stockholders, Neoleukin's stockholders approved an increase in the number of shares of the Company's authorized common stock from 20,000,000 shares to 500,000,000 shares in connection with the anticipated closing of the Merger. As a result of the reverse stock split, proportionate adjustments will be made to the exercise prices and number of shares of Neoleukin’s common stock underlying the Company’s outstanding equity awards and pre-funded warrants for common stock, as well as the number of shares of common stock issuable under the Company’s equity incentive plan and employee stock purchase plan. There will be no change to the par value per share.]]>https://www.globenewswire.com/news-release/2023/09/22/2747927/0/en/Neoleukin-Therapeutics-Announces-1-for-5-Reverse-Stock-Split.html?f=22&fvtc=4&fvtv=21142Neoleukin Therapeutics Announces 1-for-5 Reverse Stock Split2023-09-22T12:00:00Z<![CDATA[SEATTLE, Sept. 22, 2023 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” or the “Company” (NASDAQ:NLTX), a biopharmaceutical company that has designed de novo protein therapeutics utilizing sophisticated computational methods, today announced that its Board of Directors (“Board”) has approved a reverse stock split of the Company’s outstanding shares of common stock at a ratio of 1-for-5. The reverse stock split will become effective at 12:01 a.m. Eastern time on September 25, 2023. Neoleukin’s common stock will begin trading on a post-reverse stock split basis on September 25, 2023, under Neoleukin’s existing trading symbol “NLTX” with a new CUSIP number 64049K203. The reverse stock split is part of Neoleukin’s plan to regain compliance with Nasdaq’s minimum bid price requirement of $1.00 per share.]]>https://www.globenewswire.com/news-release/2023/07/18/2706252/0/en/Neurogene-and-Neoleukin-Announce-Definitive-Merger-Agreement.html?f=22&fvtc=4&fvtv=21142Neurogene and Neoleukin Announce Definitive Merger Agreement2023-07-18T10:30:00Z<![CDATA[NEW YORK and SEATTLE, July 18, 2023 (GLOBE NEWSWIRE) -- Neurogene Inc., a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, and Neoleukin Therapeutics, Inc. (NASDAQ:NLTX) today announced that they have entered into a definitive merger agreement to combine the companies in an all-stock transaction. The combined company will focus on advancing Neurogene’s pipeline of differentiated genetic medicines, including NGN-401, a clinical-stage product for Rett syndrome, which uses novel gene regulation technology for a potential best-in-class profile. Upon completion of the merger, which is subject to approval by Neurogene and Neoleukin stockholders, the combined company is expected to operate under the name Neurogene Inc. and trade on the Nasdaq Capital Market under the ticker symbol “NGNE”.]]>https://www.globenewswire.com/news-release/2023/03/08/2623560/0/en/Neoleukin-Therapeutics-Provides-Strategic-Update-and-Announces-Restructuring-and-Leadership-Transition.html?f=22&fvtc=4&fvtv=21142Neoleukin Therapeutics Provides Strategic Update and Announces Restructuring and Leadership Transition2023-03-08T22:00:00Z<![CDATA[SEATTLE, March 08, 2023 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced that it has engaged SVB Securities to assist in reviewing strategic alternatives for the Company with the goal of maximizing shareholder value. Such alternatives may include a sale, merger, divestiture of assets, licensing or other strategic transaction. There can be no assurance that the exploration of strategic alternatives will result in any agreements or transactions, or that, if completed, any agreements or transactions will be successful or on attractive terms. Neoleukin does not expect to disclose or provide an update concerning developments related to this process until the Company enters into definitive agreements or arrangements with respect to a transaction or otherwise determines that other disclosure is necessary or appropriate.]]>https://www.globenewswire.com/news-release/2022/12/12/2572217/0/en/Neoleukin-Therapeutics-Presents-Preclinical-Data-on-NEO-TRA1-at-American-Society-of-Hematology-ASH-Annual-Meeting.html?f=22&fvtc=4&fvtv=21142Neoleukin Therapeutics Presents Preclinical Data on NEO-TRA1 at American Society of Hematology (ASH) Annual Meeting2022-12-12T18:00:00Z<![CDATA[Targeted, precision-tuned agonist of IL-2 receptor selectively expands regulatory T cells Targeted, precision-tuned agonist of IL-2 receptor selectively expands regulatory T cells]]>https://www.globenewswire.com/news-release/2022/11/14/2555436/0/en/Neoleukin-Therapeutics-Announces-Third-Quarter-2022-Financial-Results-and-Corporate-Update.html?f=22&fvtc=4&fvtv=21142Neoleukin Therapeutics Announces Third Quarter 2022 Financial Results and Corporate Update2022-11-14T21:03:00Z<![CDATA[-- Development of NL-201 to be discontinued for strategic reasons ---- Company to focus on next-generation de novo proteins and core technology ---- Company restructuring to extend cash runway into the second half of 2025 --SEATTLE, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced financial results for the third quarter ended September 30, 2022 as well as a strategic decision to discontinue development of NL-201, a fully de novo IL-2/IL-15 agonist, and focus on advancing next-generation de novo protein therapeutics based on Neoleukin's expertise in designing and testing novel cytokine mimetics and experience with advanced machine learning.]]>https://www.globenewswire.com/news-release/2022/11/03/2547817/0/en/Neoleukin-Therapeutics-Announces-Oral-Presentation-at-64th-American-Society-of-Hematology-ASH-Annual-Meeting.html?f=22&fvtc=4&fvtv=21142Neoleukin Therapeutics Announces Oral Presentation at 64th American Society of Hematology (ASH) Annual Meeting2022-11-03T13:05:00Z<![CDATA[SEATTLE, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced an oral presentation at the upcoming American Society of Hematology (ASH) Annual Meeting and Exposition taking place December 10-13, 2022 in New Orleans, Louisiana.]]>https://www.globenewswire.com/news-release/2022/08/09/2495267/0/en/Neoleukin-Therapeutics-Announces-Second-Quarter-2022-Financial-Results-Provides-Corporate-Update.html?f=22&fvtc=4&fvtv=21142Neoleukin Therapeutics Announces Second Quarter 2022 Financial Results & Provides Corporate Update2022-08-09T20:02:00Z<![CDATA[Company to Host Conference Call Today, August 9, 2022, at 1:30 p.m. Pacific / 4:30 p.m. Eastern Company to Host Conference Call Today, August 9, 2022, at 1:30 p.m. Pacific / 4:30 p.m. Eastern]]>https://www.globenewswire.com/news-release/2022/08/03/2491338/0/en/Neoleukin-Therapeutics-to-Present-at-Canaccord-Genuity-42nd-Annual-Growth-Conference.html?f=22&fvtc=4&fvtv=21142Neoleukin Therapeutics to Present at Canaccord Genuity 42nd Annual Growth Conference2022-08-03T12:00:00Z<![CDATA[SEATTLE, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced that Jonathan Drachman, M.D., Chief Executive Officer, will present at the Canaccord Genuity 42nd Annual Growth Conference on Wednesday, August 10, 2022 at 1 p.m. Eastern.]]>https://www.globenewswire.com/news-release/2022/07/27/2486811/0/en/Neoleukin-Therapeutics-to-Host-Second-Quarter-2022-Financial-Results-Conference-Call-and-Webcast-on-August-9-2022.html?f=22&fvtc=4&fvtv=21142Neoleukin Therapeutics to Host Second Quarter 2022 Financial Results Conference Call and Webcast on August 9, 20222022-07-27T12:00:00Z<![CDATA[SEATTLE, July 27, 2022 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., "Neoleukin” (NASDAQ:NLTX), today announced it will report second quarter 2022 financial results on Tuesday, August 9, 2022 after the close of financial markets and then host a conference call and live audio webcast to discuss these results and provide a corporate update. Details of the event are as follows:]]>